Table 2.
Comparison With Retrospective Studies
| Parameter | GoYLC2020 | Galvez-Nino et al.25 | Chen et al.21 | Liu et al.20 | Pan et al.24 | Tanaka et al.23 | Sacher et al.4 | Wang et al.22 |
|---|---|---|---|---|---|---|---|---|
| Patient age evaluated | <40 | <40 | <35 | <35 | <40 | <40a | <40a | <30 |
| Tumor type | ||||||||
| N | 133 | 166 | 89 | 82 | 270 | 81 | 81 | 41 |
| Adenocarcinoma, n (%) | 115 (86.5) | 105 (63.3) | 89 (100) | 37 (45.1) | 194 (71.8) | 81 (100) | 68 (84.0) | 32 (78.0) |
| SCLC, n (%) | 6 (4.5) | — | — | 21 (25.9) | 18 (6.7) | — | — | 2 (4.9) |
| Squamous cell, n (%) | 9 (6.8) | 13 (7.8) | — | 9 (11.0) | 42 (15.6) | — | 3 (3.7) | 1 (2.4) |
| Stage | ||||||||
| N | 130 | 137b | 89 | 63 | 252 | 81 | 81 | 39b |
| I-III, n (%) | 27 (20.8) | 10 (7.3) | 74 (83.1) | 32 (50.8) | 84 (33.3) | 23 (28.4) | 28 (34.6) | 19 (48.7) |
| IV, n (%) | 103 (79.2) | 116 (84.7) | 15 (16.9) | 31 (49.2) | 159 (63.1) | 58 (71.6) | 53 (65.4) | 20 (51.2) |
| Unknown/other, n (%) | — | 11 (8.1) | — | — | 9 (3.6) | — | — | — |
| Mutations | ||||||||
| N | 128 | 0 | 89 | 18 | —c,d | 81 | —d | 22c |
| EGFR, n (%) | 36 (28.1) | — | 19 (21.4) | 10 (55.6) | 29 (39.7)e | 24 (29.6) | 25 (32.1)f | 5 (22.7) |
| ALK, n (%) | 42 (32.8) | — | 15 (16.9) | 5 (27.8) | 25 (33.8)g | 33 (40.7) | 13 (19.1)h | 6 (27.2) |
| Mutation negative, n (%) | 13 (10.2) | — | 29 (32.6) | 3 (16.7) | — | 22 (27.1) | — | 7 (31.8) |
| Smoking, n (%) | ||||||||
| N | 121 | 137b | 89 | 81 | 252 | 81 | 81 | 41 |
| Smoking, n (%) | 33 (27.2) | 17 (14.4) | 9 (10.1) | 23 (28.4) | 48 (19.0) | 36 (44.4) | 27 (33.3) | 5 (12.2) |
| Nonsmoking, n (%) | 88 (72.8) | 101 (73.7) | 80 (89.9) | 58 (71.6) | 196 (77.8) | 45 (55.6) | 54 (66.7) | 36 (87.8) |
| Unknown/not registered, n (%) | — | 19 (13.9) | — | — | 8 (3.2) | — | — | |
Patients less than 40 were a subgroup within the study.
Patients with NSCLC only.
Patients with adenocarcinoma only.
Number of patients with data available for EGFR and ALK mutations differed between groups.
n = 73.
n = 78.
n = 74.
n = 68.